Key Details
Price
$0.02Annual ROE
-278.72%Beta
0.04Events Calendar
Next earnings date:
Mar 7, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 7, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 25, 2021Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.
Viracta Therapeutics (NASDAQ: VIRX ) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX stock higher is its diluted earnings per share of -25 cents.
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile -
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced that Michael Faerm has been appointed as the new Chief Financial Officer and was granted a non-qualified stock option to purchase 500,000 shares of common stock. The Board of Directors also approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. The options vest over four years, with 25% vesting on May 13, 2025, and the remaining 75% vesting in equal monthly increments over the next 36 months, contingent on continuous service to Viracta. The exercise price for each option is $0.804 per share, based on the closing price on May 14, 2024.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.
FAQ
- What is the ticker symbol for Viracta Therapeutics?
- Does Viracta Therapeutics pay dividends?
- What sector is Viracta Therapeutics in?
- What industry is Viracta Therapeutics in?
- What country is Viracta Therapeutics based in?
- When did Viracta Therapeutics go public?
- Is Viracta Therapeutics in the S&P 500?
- Is Viracta Therapeutics in the NASDAQ 100?
- Is Viracta Therapeutics in the Dow Jones?
- When was Viracta Therapeutics's last earnings report?
- When does Viracta Therapeutics report earnings?
- Should I buy Viracta Therapeutics stock now?